表紙
市場調查報告書

狼瘡性腎炎:全球臨床實驗趨勢

Lupus Nephritis Global Clinical Trials Review, H2, 2019

出版商 GlobalData 商品編碼 242615
出版日期 內容資訊 英文 173 Pages
訂單完成後即時交付
價格
狼瘡性腎炎:全球臨床實驗趨勢 Lupus Nephritis Global Clinical Trials Review, H2, 2019
出版日期: 2019年12月09日內容資訊: 英文 173 Pages
簡介

本報告提供狼瘡性腎炎臨床實驗相關之最新趨勢分析,提供您各地區的臨床實驗數量,臨床實驗的各階段進展,實驗對像採用狀況,有潛力的贊助商,各企業和研究機關的研究進展,有潛力的藥劑比較等資訊。

簡介

  • 狼瘡性腎炎
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲的主要5個國家臨床實驗數量
    • 中南美的主要5個國家臨床實驗數量

G7各國臨床實驗數量:免疫疾病治療藥臨床實驗上狼瘡性腎炎的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:免疫疾病治療藥臨床實驗上狼瘡性腎炎的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

狼瘡性腎炎治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介

  • 主要企業臨床實驗概要
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Astellas Pharma Inc.
    • Biogen, Inc.
    • Johnson & Johnson
    • Immune Tolerance Network
    • E. Merck KG
    • Anthera Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Aurinia Pharmaceuticals Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • Nanjing University
    • Chinese University of Hong Kong
    • National Institute of Arthritis and Musculoskeletal and Skin Diseases
    • The National Institute of Allergy and Infectious Diseases
    • All India Institute of Medical Sciences
    • Chulalongkorn University
    • Sun Yat-sen University
    • Tuen Mun Hospital
    • Assistance Publique Hopitaux De Marseille
    • Cambridge University Hospitals NHS Foundation Trust

5個有代表性的臨床實驗簡介

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC5181CTIDB

GlobalData's clinical trial report, "Lupus Nephritis Global Clinical Trials Review, H2, 2019" provides an overview of Lupus Nephritis clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 28
  • Subjects Recruited Over a Period of Time 29
  • Clinical Trials by Sponsor Type 30
  • Prominent Sponsors 31
  • Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials 33
  • Prominent Drugs 35
  • Latest Clinical Trials News on Lupus Nephritis 36
  • Nov 11, 2019: Genentech's Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared To Standard of Care Alone 36
  • Nov 08, 2019: Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week 36
  • Nov 06, 2019: Equillium to present new data and insights on the CD6-ALCAM pathway in Lupus Nephritis at ACR 2019 37
  • Oct 16, 2019: Aurinia reports last patient study visit in Aurora phase 3 lupus nephritis study and provides update on ATM facility 37
  • Oct 11, 2019: Apellis to present data on APL-2 in complement 3 Glomerulopathy at ASN Kidney Week 2019 38
  • Oct 01, 2019: Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update 38
  • Sep 25, 2019: Omeros announces publication of study showing that inhibition of MASP-2, the key enzyme of the complement system's Lectin Pathway, protects against renal injury caused by Proteinuria 39
  • Sep 19, 2019: Roche receives FDA breakthrough status for lupus nephritis drug 39
  • Clinical Trial Profile Snapshots 40

Appendix 176

  • Abbreviations 176
  • Definitions 176
  • Research Methodology 177
  • Secondary Research 177
  • About GlobalData 178
  • Contact Us 178
  • Source 179

List of Tables

  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Region, 2019* 8
  • Lupus Nephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Lupus Nephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
  • Lupus Nephritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
  • Lupus Nephritis Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
  • Lupus Nephritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15
  • Lupus Nephritis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, G7 Countries (%), 2019* 17
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, E7 Countries (%), 2019* 20
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 23
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Phase, 2019* 24
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 25
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Trial Status, 2019* 27
  • Lupus Nephritis Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29
  • Lupus Nephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 30
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 32
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 34
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 35

List of Figures

  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
  • Lupus Nephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
  • Lupus Nephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
  • Lupus Nephritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
  • Lupus Nephritis Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
  • Lupus Nephritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15
  • Lupus Nephritis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, G7 Countries (%), 2019* 17
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, E7 Countries (%), 2019* 20
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 22
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Phase (%), 2019* 24
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 25
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Trial Status, 2019* 26
  • Lupus Nephritis Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29
  • Lupus Nephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 30
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 31
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 33
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 35
  • GlobalData Methodology 177